AI-powered search

Therapeutic Hotline: Acne, Rosacea, AKs, Eczema, and Others

Featuring Gary Goldenberg, MD | Co-Director |

Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

| Published November 03, 2023

In this session, Gary Goldenberg, MD, took the audience on a whirlwind tour through the latest in treatment updates for common dermatologic conditions. Starting off with acne and rosacea, Dr Goldenberg reviewed efficacy data for a new fixed-dose combination product currently in clinical trials: clindamycin 1.2% + benzoyl peroxide 3.1% + adapalene 0.15% gel (IDP-126). In a Phase 2 study, IDP-126 gel showed superior efficacy in reducing inflammatory and noninflammatory lesions than other fixed-dose combination products (CLIN/BPO, BPO/ADAP, CLIN/ADAP). Dr Goldenberg also reviewed data for clascoterone 1% cream, a novel 1726 nm laser recently approved for mild, moderate, and severe acne and a photopneumatic acne therapy system. 

Moving on to atopic dermatitis, Dr Goldenberg discussed the impressive efficacy of both upadacitinib and abrocitinib before introducing tapinarof cream 1%, which is currently under investigation for use in atopic dermatitis. Transitioning to new nonsteroidal topical treatments of psoriasis, tapinarof cream 1% daily led to 64% of patients achieving PASI-75 responses at any time point in a pooled Phase 3 trial analysis. Apremilast appears to be safe and efficacious for pediatric patients with moderate-to-severe plaque psoriasis, with 45.4% achieving PASI-75 at Week 16 compared to 16.1% of those on placebo. Dr Goldenberg concluded the discussion on psoriasis with an overview of recently released data for several biologic medications, including secukinumab, ixekizumab, and risankizumab. 

Transitioning to medications currently under investigation, roflumilast foam 0.3% was shown to be effective for seborrheic dermatitis in Phase 2 trials. Monotherapy with nemolizumab, an IL-31R inhibitor, led to statistically significant improvements in itch scores compared to placebo in patients with prurigo nodularis in Phase 3 trials, and secukinumab was statistically superior to placebo in reducing abscesses and inflammatory nodules in hidradenitis suppurativa compared to placebo in Phase 3 trials. Dr Goldenberg concluded this action-packed session with an update on useful technology for dermatologists, including a pigmented lesion assay and electrical impedance spectroscopy machine to assist in melanoma diagnosis, as well as gene expression profiling tests to assist with risk stratification for patients with melanoma and cutaneous squamous cell carcinoma. With all of these new medications and technologies, it is certainly a great time to be a dermatologist!


Related Media

Powered by Polaris TM

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved